Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET

Company Participants

Rachel Frank - Associate Director, IR

Sanj Patel - CEO

Ross Moat - SVP and CCO

Mark Ragosa - SVP and CFO

John Paolini - SVP and CMO

Conference Call Participants

Anupam Rama - JPMorgan

Paul Choi - Goldman Sachs

David Nierengarten - Wedbush Securities

Liisa Bayko - Evercore ISI

Operator

Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

And I would now like to hand the conference over to your speaker today, Ms. Rachel Frank. Please go ahead.

Rachel Frank

Thank you, operator. Good morning everyone and thank you for joining Kiniksa's call to discuss our third quarter 2023 financial results and recent portfolio execution. Press release highlighting these results can be found on our website under the Investors section.

As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction; Ross Moat, our Chief Commercial Officer, will provide an update on our commercial execution; John Paolini, our Chief Medical Officer, will provide a KPL-404 forum review; then Mark Ragosa, our Chief Financial Officer, who will review our third quarter 2023 financial results. And finally, Sanj will return for closing remarks and to kick off the Q&A session.

Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements.

A review of such statements and risk factors can be found on this slide as well as under the caption Risk Factors contained in our SEC filings. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements, except as required by law.

With that, I will turn it over to Sanj.

Sanj Patel

Thanks Rachel and good morning everyone. I'm happy to review our third quarter 2023 financial results today. We continued to advance all aspects of our business, including strong revenue growth with ARCALYST and clinical trial execution with KPL-404.

On the commercial side, Q3 represented another quarter of growth for ARCALYST with a net product revenue of $64.8 million. We continue to execute commercially, and we have seen strong prescriber adoption and patient enrollments in the third quarter.